ASX - By Stock
|
SPL |
Re:
UIL Limited increase stake in Starpharma
|
|
juxtaposer
|
11 |
1.7K |
4 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
11
|
1.7K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Wealth Destroyer - Down 96%
|
|
juxtaposer
|
13 |
2.9K |
1 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
13
|
2.9K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in Director's Interest Notice - Jeff Davies
|
|
juxtaposer
|
2 |
834 |
3 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
2
|
834
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
2 |
29/06/24 |
29/06/24 |
ASX - By Stock
|
25
|
4.3K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
2 |
29/06/24 |
29/06/24 |
ASX - By Stock
|
25
|
4.3K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
1 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
25
|
4.3K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
0 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
25
|
4.3K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
3 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
25
|
4.3K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
5 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
25
|
4.3K
|
5
|
|
ASX - By Stock
|
SPL |
Accelerated Approval?
|
|
juxtaposer
|
25 |
4.3K |
5 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
25
|
4.3K
|
5
|
|
ASX - By Stock
|
AMT |
Re:
Ann: Recommended cash takeover offer by Allegra Innovations PL
|
|
juxtaposer
|
3 |
805 |
0 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
3
|
805
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Priority and Breakthrough Drugs -FDA
|
|
juxtaposer
|
4 |
801 |
3 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
4
|
801
|
3
|
|
ASX - By Stock
|
SPL |
Re:
New indications for irinotecan
|
|
juxtaposer
|
19 |
4.2K |
2 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
19
|
4.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
New indications for irinotecan
|
|
juxtaposer
|
19 |
4.2K |
6 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
19
|
4.2K
|
6
|
|
ASX - By Stock
|
SPL |
Priority and Breakthrough Drugs -FDA
|
|
juxtaposer
|
4 |
801 |
8 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
4
|
801
|
8
|
|
ASX - By Stock
|
SPL |
The Race to Replace Chemo - Bloomberg
|
|
juxtaposer
|
0 |
236 |
0 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
0
|
236
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive final DEP irinotecan Phase 2 clinical trial results
|
|
juxtaposer
|
42 |
10K |
1 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
42
|
10K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive final DEP irinotecan Phase 2 clinical trial results
|
|
juxtaposer
|
42 |
10K |
1 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
42
|
10K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive final DEP irinotecan Phase 2 clinical trial results
|
|
juxtaposer
|
42 |
10K |
6 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
42
|
10K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
C'mon Friday 24th May
|
|
juxtaposer
|
12 |
3.1K |
2 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
12
|
3.1K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
C'mon Friday 24th May
|
|
juxtaposer
|
12 |
3.1K |
4 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
12
|
3.1K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
WB is selling at $15
|
|
juxtaposer
|
9 |
3.2K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
9
|
3.2K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
WB is selling at $15
|
|
juxtaposer
|
9 |
3.2K |
2 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
9
|
3.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in Director's Interest Notice - R Thomas
|
|
juxtaposer
|
9 |
2.4K |
9 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
9
|
2.4K
|
9
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
|
|
juxtaposer
|
150 |
31K |
6 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
150
|
31K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Good news!
|
|
juxtaposer
|
13 |
3.7K |
7 |
03/02/24 |
03/02/24 |
ASX - By Stock
|
13
|
3.7K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
Clinical trial thoughts
|
|
juxtaposer
|
40 |
7.8K |
2 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
40
|
7.8K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Clinical trial thoughts
|
|
juxtaposer
|
40 |
7.8K |
6 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
40
|
7.8K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Clinical trial thoughts
|
|
juxtaposer
|
40 |
7.8K |
0 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
40
|
7.8K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
VIRALEZE™ nasal spray a blow for covid
|
|
juxtaposer
|
37 |
6.5K |
2 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
37
|
6.5K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
DEP Deals
|
|
juxtaposer
|
6 |
1.5K |
4 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
6
|
1.5K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Viraleze shows antiviral efficacy in COVID-19 patients
|
|
juxtaposer
|
74 |
15K |
8 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
74
|
15K
|
8
|
|
ASX - By Stock
|
SPL |
Scripps Eric Topol on nasal spray
|
|
juxtaposer
|
1 |
409 |
4 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
1
|
409
|
4
|
|
ASX - By Stock
|
SPL |
Re:
New CEO’s focus
|
|
juxtaposer
|
85 |
19K |
3 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
85
|
19K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
juxtaposer
|
133 |
29K |
12 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
133
|
29K
|
12
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
juxtaposer
|
133 |
29K |
7 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
133
|
29K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
|
|
juxtaposer
|
50 |
13K |
3 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
50
|
13K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
REBIRTH OR REINVENTION OF STARPHARMA
|
|
juxtaposer
|
38 |
9.6K |
6 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
38
|
9.6K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in substantial holding
|
|
juxtaposer
|
32 |
8.4K |
3 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
32
|
8.4K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Partnered Program Update
|
|
juxtaposer
|
43 |
15K |
2 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
43
|
15K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Clinical Trial Update
|
|
juxtaposer
|
69 |
21K |
3 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
69
|
21K
|
3
|
|
ASX - By Stock
|
AMT |
Re:
Ann: AMT Submits 510(k) for Spinal Cage FDA Clearance
|
|
juxtaposer
|
7 |
2.7K |
0 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
7
|
2.7K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Exciting year for CEO
|
|
juxtaposer
|
21 |
5.2K |
3 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
21
|
5.2K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
I dare you
|
|
juxtaposer
|
14 |
3.4K |
4 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
14
|
3.4K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
BREAKING: DEP completion guidance
|
|
juxtaposer
|
11 |
3.2K |
1 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
11
|
3.2K
|
1
|
|
ASX - By Stock
|
SPL |
Biden $5B search for Covid nasal spray.
|
|
juxtaposer
|
1 |
396 |
1 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
1
|
396
|
1
|
|
ASX - By Stock
|
SPL |
Re:
New TGA rules on nanoparticles for medical devices
|
|
juxtaposer
|
28 |
8.2K |
2 |
09/04/23 |
09/04/23 |
ASX - By Stock
|
28
|
8.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
New TGA rules on nanoparticles for medical devices
|
|
juxtaposer
|
28 |
8.2K |
3 |
07/04/23 |
07/04/23 |
ASX - By Stock
|
28
|
8.2K
|
3
|
|
ASX - By Stock
|
AMT |
Re:
Ann: Large Animal Study Completed Showing Positive Results
|
|
juxtaposer
|
5 |
1.4K |
1 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
5
|
1.4K
|
1
|
|
ASX - By Stock
|
AMT |
Re:
Ann: Large Animal Study Completed Showing Positive Results
|
|
juxtaposer
|
5 |
1.4K |
0 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
5
|
1.4K
|
0
|
|